209 related articles for article (PubMed ID: 38115004)
1. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.
Cinti F; Leccisotti L; Sorice GP; Capece U; D'Amario D; Lorusso M; Gugliandolo S; Morciano C; Guarneri A; Guzzardi MA; Mezza T; Capotosti A; Indovina L; Ferraro PM; Iozzo P; Crea F; Giordano A; Giaccari A
Cardiovasc Diabetol; 2023 Dec; 22(1):349. PubMed ID: 38115004
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Leccisotti L; Cinti F; Sorice GP; D'Amario D; Lorusso M; Guzzardi MA; Mezza T; Gugliandolo S; Cocchi C; Capece U; Indovina L; Ferraro PM; Iozzo P; Crea F; Giordano A; Giaccari A
Cardiovasc Diabetol; 2022 Sep; 21(1):173. PubMed ID: 36057768
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
[TBL] [Abstract][Full Text] [Related]
4. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus.
Song XT; Wei YL; Rui YF; Fan L
J Diabetes Complications; 2023 Jul; 37(7):108509. PubMed ID: 37235925
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Sorice GP; Cinti F; Leccisotti L; D'Amario D; Lorusso M; Guzzardi MA; Mezza T; Cocchi C; Capece U; Ferraro PM; Crea F; Giordano A; Iozzo P; Giaccari A
Diabetes Ther; 2021 Jul; 12(7):2101-2113. PubMed ID: 34037951
[TBL] [Abstract][Full Text] [Related]
6. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
Sato T; Aizawa Y; Yuasa S; Fujita S; Ikeda Y; Okabe M
J Atheroscler Thromb; 2020 Dec; 27(12):1348-1358. PubMed ID: 32115470
[TBL] [Abstract][Full Text] [Related]
8. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
9. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
Iacobellis G; Gra-Menendez S
Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
[TBL] [Abstract][Full Text] [Related]
10. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment.
Couselo-Seijas M; Agra-Bermejo RM; Fernández AL; Martínez-Cereijo JM; Sierra J; Soto-Pérez M; Rozados-Luis A; González-Juanatey JR; Eiras S
Atherosclerosis; 2020 Jan; 292():60-69. PubMed ID: 31783199
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Marfella R; Prattichizzo F; Sardu C; Rambaldi PF; Fumagalli C; Marfella LV; La Grotta R; Frigé C; Pellegrini V; D'Andrea D; Cesaro A; Calabrò P; Pizzi C; Antonicelli R; Ceriello A; Mauro C; Paolisso G
Cardiovasc Diabetol; 2024 Jan; 23(1):10. PubMed ID: 38184582
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
15. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
[TBL] [Abstract][Full Text] [Related]
16. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
17. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study.
Chen J; Chang J; Shi Q; Li X; Wang L; Zhao H
BMC Cardiovasc Disord; 2023 Oct; 23(1):495. PubMed ID: 37805494
[TBL] [Abstract][Full Text] [Related]
19. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
